news
New data for baricitinib in rheumatoid arthritis presented at EULAR
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
List view / Grid view
Rheumatoid arthritis (RA)
news
Bristol-Myers Squibb shares significant new findings in rheumatoid arthritis research
8 June 2016 | By Mandy Parrett, Editorial Assistant
Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
news
Sirukumab meets both co-primary endpoints in rheumatoid arthritis study
8 June 2016 | By Victoria White, Digital Content Producer
The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
news
Lilly and Incyte announce results from RA-BEACON baricitinib study
Lilly and Incyte have announced results from the RA-BEACON Phase III study of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis (RA).
news
sarilumab demonstrates superiority to adalimumab in rheumatoid arthritis
11 March 2016 | By Victoria White
A Phase III study demonstrated that sarilumab was superior to adalimumab in improving signs and symptoms in patients with active RA...
news
Golimumab shows higher treatment persistence rates in patients with IMRD
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
Lilly and Incyte submit NDA for baricitinib to the FDA
Lilly and Incyte have announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
news
Phase III study of sirukumab in giant cell arteritis starts
27 November 2015 | By Victoria White
Sirukumab is an investigational human anti-IL-6 monoclonal antibody that selectively binds with high affinity to the IL-6 cytokine...
news
Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis
Baricitinib demonstrated superiority over adalimumab (Humira) after 12 weeks based on several critical measures of rheumatoid arthritis disease activity...
news
Baricitinib demonstrates superiority to adalimumab in rheumatoid arthritis
Lilly and Incyte have announced positive topline results from the fourth successful Phase 3 study (RA-BEAM ) of baricitinib.
news
Baricitinib superior to methotrexate in rheumatoid arthritis
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
news
Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
news
Asia-Pacific rheumatoid arthritis treatment market value will reach $7 billion by 2021
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
news
Sanofi and Regeneron announce positive topline results from Phase 3 studies with sarilumab in patients with rheumatoid arthritis
21 May 2015 | By Victoria White
Phase 3 study of sarilumab met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis...
